CD317, also known as BST-2 (bone marrow stromal antigen 2) and Tetherin, is a single pass type Ⅱ transmembrane protein with a unique topology. CD317 consists of an N-terminal cytoplasmic tail, followed by a transmembrane domain, an extracellular domain or loop, and a C-terminal GPI-linkage. The extracellular loop contains a coiled coil domain that forms a long semi-flexible rod-like structure, which may be important for virion retention at the cell surface and prevention of virus spreading. In addition the GPI anchor is essential for its antiviral activity. CD317 is expressed predominantly in liver, lung, heart and placenta.  It is also expressed on bone marrow stromal cells and is upregulated in breast cancer, astrocytoma, and multiple myeloma cells. CD317 is highly expressed during B-cell development, from pro-B precursors to plasma cells, and on T-cells, monocytes, NK cells and dendritic cells. CD317 is involved in B-cell development and growth. CD317 is an interferon (IFN)-induced antiviral host restriction factor that efficiently blocks the release of diverse mammalian enveloped viruses by directly tethering nascent virions to the membranes of infected cells. CD317 is active against at least 4 virus families: retroviruses, filoviruses, arenaviruses, and herpesviruses.  CD317 can act as an inhibitor to HIV-1 infection in the absence of Vpu and inhibit the release of other viruses such as the Lassa, Marburg virions, and Kaposi sarcoma virus. CD317 binds to ILT7 on plasmacytoid dendritic cells and may provide negative feedback to the production of IFN by plasmacytoid dendritic cells in response to viral infection.  

CD317, also known as BST-2 (bone marrow stromal antigen 2) and Tetherin, is a single pass type Ⅱ transmembrane protein with a unique topology. CD317 consists of an N-terminal cytoplasmic tail, followed by a transmembrane domain, an extracellular domain or loop, and a C-terminal GPI-linkage. The extracellular loop contains a coiled coil domain that forms a long semi-flexible rod-like structure, which may be important for virion retention at the cell surface and prevention of virus spreading. In addition the GPI anchor is essential for its antiviral activity. CD317 is expressed predominantly in liver, lung, heart and placenta.  It is also expressed on bone marrow stromal cells and is upregulated in breast cancer, astrocytoma, and multiple myeloma cells. CD317 is highly expressed during B-cell development, from pro-B precursors to plasma cells, and on T-cells, monocytes, NK cells and dendritic cells. CD317 is involved in B-cell development and growth. CD317 is an interferon (IFN)-induced antiviral host restriction factor that efficiently blocks the release of diverse mammalian enveloped viruses by directly tethering nascent virions to the membranes of infected cells. CD317 is active against at least 4 virus families: retroviruses, filoviruses, arenaviruses, and herpesviruses.  CD317 can act as an inhibitor to HIV-1 infection in the absence of Vpu and inhibit the release of other viruses such as the Lassa, Marburg virions, and Kaposi sarcoma virus. CD317 binds to ILT7 on plasmacytoid dendritic cells and may provide negative feedback to the production of IFN by plasmacytoid dendritic cells in response to viral infection.  

 

Product Details

 

Gene Symbol: CD317; BST2; BST-2; Tetherin

 

NCBI Gene ID: 684

 

Uniprot Entry: Q10589

 

Construct Details: The recombinant human CD317-Fc is expressed as a 349-amino acid protein consisting of  Ser50 -  Ser161 region of CD317 and a C-terminal Fc from human IgG1, which exists as a dimer under non-reducing conditions.   

   

Source: Human cells stably expressing human CD317-Fc and growing in chemical-defined media with no animal components or antibiotics

 

Deduced Amino Acid Sequence: 

        10         20         30         40         50         60 

SEACRDGLRA VMECRNVTHL LQQELTEAQK GFQDVEAQAA TCNHTVMALM ASLDAEKAQG 

        70         80         90        100        110        120 

QKKVEELEGE ITTLNHKLQD ASAEVERLRR ENQVLSVRIA DKKYYPSSQD SSTTENLYFQ 

       130        140        150        160        170        180 

GSTGTHTCPP CPAPELLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY 

       190        200        210        220        230        240 

VDGVEVHNAK TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK 

       250        260        270        280        290        300 

AKGQPREPQV YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 

       310        320        330        340 

DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 

  

M.W.: Calculated molecular mass (kDa): 39.1; Estimated by SDS-PAGE under reducing condition (kDa): ~55

 

Calculated PI: 5.97

 

Calculated extinction coefficients (M-1 cm-1, at 280nm): 40380

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as "DTT: +")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBSpH7.4 (carrier & preservative free). 

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Binds to its ligand human ILT7 protein and blocks its signaling activity.

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 6 months. 

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. Genomics 26:527-534(1995) 

2. Cell. Immunol. 236:6-16(2005)

3. Nature 451:425-430(2008)

4. Cell 139:499-511(2009)

5. J. Exp. Med. 206:1603-1614(2009) 

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: FCL2538-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.